Komori
Governance4889Renascience Inc.Pharmaceuticals

Notice of Partial Amendments to the Articles of Incorporation

Subject to approval at the shareholders meeting, the Company will add the operation of medical institutions, the provision of outsourced services related to the operation of medical institutions, other medical businesses, and related consulting services to the business purposes set out in its Articles of Incorporation. The effective date is scheduled for 25 June 2026.

Worth reading
—
Scored from 0 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Contents of this filing

Changes this time

A new item will be added to Article 2 of the Articles of Incorporation covering the operation of medical institutions, the provision of outsourced services related to the operation of medical institutions and other medical institution operations, other medical businesses, and consulting services related to those businesses. The existing item 4 will be renumbered as item 5.

この書類は、機関設計や取締役会の構成そのものは述べていません。上に示したのは、この書類が述べている変更点です。

Contents of this filing
ItemDetails
Changes this timeA new item will be added to Article 2 of the Articles of Incorporation covering the operation of medical institutions, the provision of outsourced services related to the operation of medical institutions and other medical institution operations, other medical businesses, and consulting services related to those businesses. The existing item 4 will be renumbered as item 5.
Items this document does not state (7)
Corporate Governance StructureNumber of directorsNumber of independent officersCommitteePolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The Company is advancing research and development of pharmaceuticals and other products in the anti-aging and longevity fields, and will specify medical businesses as a corporate purpose in preparation for expanding its business activities going forward.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Partial Amendments to the Articles of Incorporation | Renascience Inc. (4889) timely disclosure | Komori